Rubius Therapeutics
Latest round
- Series C
Last raised
- Feb 2018
Total raised
- $246M
Investors
- 1
About Rubius Therapeutics
Rubius Therapeutics, Inc., founded in 2014, is based in Cambridge, US, and specializes in creating Red Cell Therapeutics™. The company has undergone no significant pivots in its strategy.00 mn on March 16, 2021. The company was founded by individuals with experience in the biotech sector, although specific previous ventures are not detailed.Rubius Therapeutics, Inc. specializes in the development of Red Cell Therapeutics™, which are genetically engineered red blood cells aimed at treating critical medical needs, particularly cancer and autoimmune conditions. Their leading candidates, RTX-240 and RTX-224, focus on solid tumors and leverage advanced genetic engineering to enhance the immune response against cancer cells.50 mn in 2022.Rubius Therapeutics, Inc. The company aims to enhance its clinical pipeline and expects to launch its innovative therapies in a phased manner.11 mn, are anticipated to aid in ongoing research initiatives and the commercialization of its products.
Who invested in Rubius Therapeutics
1 investor across 3 rounds
See all investors in Rubius Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Rubius Therapeutics
Who invested in Rubius Therapeutics?
Rubius Therapeutics has 1 investor on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Rubius Therapeutics raised?
Rubius Therapeutics has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Rubius Therapeutics last raise money?
Rubius Therapeutics's most recent round on record is a Series C, in Feb 2018.
What does Rubius Therapeutics do?
Rubius Therapeutics is a biotechnology company.
Where is Rubius Therapeutics headquartered?
Rubius Therapeutics is headquartered in Cambridge, US.
Which VCs invest in companies like Rubius Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Rubius Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Rubius Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.